OC 40 - Non-Replacement Therapies II

Moderator(s)

• 

  Pratima Chowdary, MD

  Consultant Haematologist
  Katharine Dormandy Haemophilia and Thrombosis Centre
  Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free London NHS Foundation Trust, London, United Kingdom
  London, England, United Kingdom
• GM

  Genevieve Moyer

  Assistant Professor
  University of Colorado
  Centennial, Colorado, United States

Presentations:

• 2:45 PM – 3:00 PM

  FRONTIER1: A Phase 1/2 Dose Escalation Study of a Novel Factor VIIIa Mimetic Bispecific Antibody, Mim8, for Evaluation of Safety, Pharmacokinetics, and Efficacy
  

  Presenting Author: Pratima Chowdary, MD – Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free London NHS Foundation Trust, London, United Kingdom

  Co-Author: Francisco José López Jaime, MD – Hemostasis and Thrombosis Unit, Regional University Hospital of Málaga, IBIMA, Málaga, Spain.

  Co-Author: Johnny Mahlangu, MD, MMed – University of the Witwatersrand and NHLS

  Co-Author: Christian Winther Eskelund – Novo Nordisk A/S

  Co-Author: Rikke Medom Meldgaard – Novo Nordisk A/S

  Co-Author: Paula Persson – Novo Nordisk A/S

  Co-Author: Jerzy Windyga, MD, PhD – Department of Hemostasis Disorders and Internal Medicine, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
• 3:00 PM – 3:15 PM

  Efficacy, Safety, and Pharmacokinetics of Emicizumab Prophylaxis in Patients with Acquired Hemophilia A: Primary Analysis Results from a Phase III Study (AGEHA)
  

  Presenting Author: Midori Shima – Thrombosis and Hemostasis Research Center, Nara Medical University, Kashihara, Japan

  Co-Author: Kagehiro Amano – Department of Laboratory Medicine, Tokyo Medical University

  Co-Author: Yoshiyuki Ogawa – Department of Hematology, Gunma University Graduate School of Medicine, Maebashi, Japan

  Co-Author: Koichiro Yoneyama, MSc – Chugai Pharmaceutical Co., Ltd., Tokyo, Japan

  Co-Author: Ryoto Ozaki – Chugai Pharmaceutical Co., Ltd., Tokyo, Japan

  Co-Author: Ryota Kobayashi – Chugai Pharmaceutical Co., Ltd., Tokyo, Japan

  Co-Author: Emiko Sakaida – Department of Hematology, Chiba University Hospital, Chiba, Japan

  Co-Author: Makoto Saito – Blood Disorders Center, Aiiku Hospital, Sapporo, Japan

  Co-Author: Takashi Okamura – Department of Hematology, St. Mary’s Hospital, Kurume, Japan

  Co-Author: Toshihiro Ito – Department of Infectious Diseases, National Hospital Organization Sendai Medical Center, Sendai, Japan

  Co-Author: Norimichi Hattori – Division of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan

  Co-Author: Satoshi Higasa – Department of Hematology, Hyogo College of Medicine Hospital, Nishinomiya, Japan

  Co-Author: Nobuaki Suzuki – Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan

  Co-Author: Yoshinobu Seki, MD, PhD – Department of Hematology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minami-uonuma, Japan

  Co-Author: Keiji Nogami – Nara Medical University, Nara, Japan
• 3:15 PM – 3:30 PM

  Consumption of On-demand Factor Concentrates and Bypassing Agents for Management of Breakthrough Bleeds with Fitusiran Prophylaxis in People with Haemophilia A or B: An Analysis of Two Phase 3 Studies
  

  Presenting Author: Alok Srivastava, MD, FRACP, FRCPA, FRCP – Christian Medical College, Vellore, India

  Co-Author: Runhui Wu – Beijing Children’s Hospital, Capital Medical University, Beijing, China

  Co-Author: Chur-Woo You – Department of Pediatrics, Daejeon Eulji Medical Center, Eulji University School of Medicine, Daejeon, South Korea

  Co-Author: Kaan Kavakli – Ege Hemophilia Center, Izmir, Turkey

  Co-Author: Jose Bartelt-Hofer – Sanofi Genzyme, Chilly-Mazarin, France

  Co-Author: Ricardo Rosim – Sanofi Genzyme, São Paulo, Brazil

  Co-Author: Zhiying Qiu – Sanofi, Bridgewater, NJ, USA

  Co-Author: Viridiana Cano – Sanofi Genzyme, Cambridge, MA, USA

  Co-Author: Shauna Andersson – Sanofi

  Co-Author: Steven W. Pipe, MD – University of Michigan, Ann Arbor, MI, USA
• 3:30 PM – 3:45 PM

  Safety and Efficacy of Emicizumab in People with Hemophilia A Enrolled in the Hemophilia Natural History Study (ATHN 7)
  

  Co-Author: Tyler W. Buckner – Hemophilia and Thrombosis Center, University of Colorado, School of Medicine

  Co-Author: Shannon L. Carpenter – Kansas City Regional Hemophilia Center

  Co-Author: Christine L. Kempton – Hemophilia of Georgia Center for Bleeding and Clotting Disorders of Emory

  Co-Author: Lucy Lee – Genentech, Inc.

  Co-Author: Lynn Malec, MD, MSc – Versiti Blood Research Institute

  Co-Author: Thomas W. McLean – Wake Forest University Health Sciences

  Co-Author: Paul Morton – Genentech, Inc.

  Co-Author: Janice M. Staber – Iowa Hemophilia and Thrombosis Center – University of Iowa

  Co-Author: Michael Wang, MD – University of Colorado Hemophilia and Thrombosis Center

  Presenting Author: Michael Recht, MD, PhD, MBA – American Thrombosis and Hemostasis Network
• 3:45 PM – 4:00 PM

  Crimson 1: A Phase 3 study to evaluate the efficacy and safety of subcutaneous marzeptocog alfa (activated) for on-demand treatment of bleed events in subjects with hemophilia A or B, with inhibitors
  

  Presenting Author: Savita Rangarajan, MD, FRCP, FRCPath – University of Southampton

  Co-Author: Shraddha Desai – Catalyst Biosciences

  Co-Author: Shashikant Apte – Sahyadri Speciality Hospital, Pune, India

  Co-Author: Dharmesh Vaghasiya – Sahyadri Super Specialty Hospital

  Co-Author: Johnny Mahlangu, MD, MMed – University of the Witwatersrand and NHLS

  Co-Author: Vijay M. Ramanan – Grant Medical Foundation, Ruby Hall Clinic

  Co-Author: Levani Makhaldiani – K.Eristavi National Centre of Experimental and Clinical Surgery

  Co-Author: Bartosz Korczowski – Institute of Medical Sciences, Medical College, University of Rzeszów

  Co-Author: Margarita Timofeeva – Federal State Budgetary Scientific Institution,Kirov Research Institute of Hematology and Blood Transfusion of Federal Medical and Biological Agency

  Co-Author: Svetlana Volkova – MEDIS, LLC

  Co-Author: Susmitha Pinnamaraju – Catalyst Biosciences

  Co-Author: Jang Yun – Catalyst Biosciences

  Co-Author: Linda Neuman – Catalyst Biosciences

  Co-Author: Tom Knudsen – Catalyst Biosciences

  Co-Author: Benjamin Kim – Catalyst Biosciences